Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 771 to 780 of 1549 total matches.

Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
retention (2%). ApplicationThe Medical Letter ® Vol. 66 (1709) August 19, 2024 134 site reactions ...
The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years old.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):133-4   doi:10.58347/tml.2024.1709c |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
from The Medical Letter • Vol. 7 (Issue 84) August 2009 with 50-100 mcg/day, but others begin with full ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Drugs for HIV Infection

   
Treatment Guidelines from The Medical Letter • Feb 01, 2014  (Issue 138)
for HIV Infection 8 Treatment Guidelines from The Medical Letter • Vol. 12 (Issue 138) • February 2014 ...
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Treat Guidel Med Lett. 2014 Feb;12(138):7-16 |  Show IntroductionHide Introduction

Antibacterial Drugs for Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
heart, lung, liver or renal disease, diabetes, alcoholism, malignancy, or 11 The Medical Letter ® Vol ...
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-5 |  Show IntroductionHide Introduction

Drugs for Hypothyroidism

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
) ................... p 27 The Medical Letter ® Vol. 65 (1670) February 20, 2023 Thyroid Function Tests (TFTs ...
Primary hypothyroidism is usually the result of Hashimoto's (autoimmune) thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine (LT4; synthetic thyroxine; Synthroid, and others) is the drug of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9   doi:10.58347/tml.2023.1670a |  Show IntroductionHide Introduction

Acetaminophen Safety

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2002  (Issue 1142)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 44 (W1142A ...
An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
Med Lett Drugs Ther. 2002 Oct 28;44(1142):91-3 |  Show IntroductionHide Introduction

Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015  (Issue 1470)
in 142 patients 86 The Medical Letter ® Vol. 57 (1470) June 8, 2015 Table 1. Some Drugs for Metastatic ...
The FDA has approved nivolumab (Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda), and the first to be approved for treatment of NSCLC.
Med Lett Drugs Ther. 2015 Jun 8;57(1470):85-7 |  Show IntroductionHide Introduction

Two New Drugs for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
dosage is 10-15 mg/kg q6h. The Medical Letter ® Vol. 56 (1449) August 18, 2014 to another glycopeptide ...
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ). Tedizolid phosphate (Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox). A third IV antibiotic, oritavancin (Orbactiv), recently approved by the FDA for the same indication, will be reviewed in a future...
Med Lett Drugs Ther. 2014 Aug 18;56(1449):73-5 |  Show IntroductionHide Introduction

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
® Vol. 62 (1614) December 28, 2020 Table 3. Some Drugs for Prevention and Treatment of PONV1 Some ...
The FDA has approved IV amisulpride (Barhemsys – Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):205-8 |  Show IntroductionHide Introduction

Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
. Accessed November 10, 2021. 189 The Medical Letter ® Vol. 63 (1638) November 29, 2021 VACCINES – PCV20 ...
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years...
Med Lett Drugs Ther. 2021 Nov 29;63(1638):188-90 |  Show IntroductionHide Introduction